BPC 157 Capsule (500mcg)
$150.00
BPC-157 (500mcg) is a research-grade synthetic pentadecapeptide formulated for laboratory research use. Originally isolated from a protein found in human gastric juice, BPC-157 has been examined in over 100 preclinical studies across multiple tissue model systems. Independently tested by a USA-based third-party laboratory. For laboratory research use only.
- ✓ 500mcg BPC-157 per unit
- ✓ Third-party tested — batch documentation included
- ✓ USA tested and fulfilled
- ✓ For laboratory research use only
BPC-157 Capsule (500mcg) — Research Overview
BPC-157 (500mcg) is a research-grade synthetic pentadecapeptide formulated for laboratory research use. Originally isolated from a protein found in human gastric juice, BPC-157 is one of the most extensively studied peptides in preclinical research, with over 100 published studies examining its behavior across multiple tissue model systems since the 1990s.
The capsule format provides a consistent unit dose for oral administration protocols in laboratory research settings. Each capsule contains 500mcg of BPC-157 at verified 99%+ purity.
What the Research Shows
The most consistently documented mechanism in BPC-157 research involves VEGFR2 activation and downstream Akt-eNOS signaling. A 2017 study published in the Journal of Molecular Medicine by Hsieh et al. confirmed BPC-157 promotes VEGFR2 internalization alongside VEGFR2-Akt-eNOS activation, increasing vessel density both in vivo and in vitro (DOI: 10.1007/s00109-016-1488-y). A 2025 systematic review in the American Journal of Sports Medicine by Vasireddi et al. examined the full available BPC-157 literature across tendon, ligament, muscle, and bone repair models (DOI: 10.1177/15563316251355551).
A study published in the Journal of Applied Physiology (DOI: 10.1152/japplphysiol.00945.2010) found that BPC-157 markedly increased fibroblast survival under oxidative stress and enhanced fibroblast migration in a dose-dependent manner. A 2020 study in Scientific Reports (PMC7555539) documented BPC-157 activation of endothelial nitric oxide synthase through VEGFR2 and AKT pathways.
As of 2026, published human data for BPC-157 consists of three small studies totaling fewer than 30 participants. All musculoskeletal findings come from animal models, primarily rodents. BPC-157 is classified as a Category 2 bulk drug substance by the FDA, restricting compounding pharmacy access in the United States. It is not approved for human or veterinary therapeutic use by any regulatory agency worldwide.
Quality Documentation
Every batch is independently tested by a USA-based third-party laboratory using HPLC with UV Detection and Mass Spectrometry. The batch-specific Certificate of Analysis is included with every order.
- 99%+ purity — HPLC and Mass Spectrometry verified
- Batch-specific COA included with every order
- USA tested and fulfilled
- 500mcg BPC-157 per capsule
Read the full BPC-157 research overview with citations →
This product is sold for laboratory research purposes only. Nothing on this page constitutes medical advice. Not intended for human or veterinary consumption.
| Weight | 1 lbs |
|---|---|
| Dimensions | 4 × 2 × 2 in |
Only logged in customers who have purchased this product may leave a review.
Certificate of Analysis
All AlphaPeps batches are independently tested by Freedom Diagnostics using HPLC analysis. Click below to view purity certificates for every lot of this compound.
View BPC 157 Capsule (500mcg) COAs →

Reviews
There are no reviews yet.